

Sorafenib-EMEA Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/S0250570DBDEN.html

Date: December 2017

Pages: 143

Price: US\$ 3,480.00 (Single User License)

ID: S0250570DBDEN

Abstracts

Report Summary

Sorafenib-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Sorafenib industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Sorafenib 2013-2017, and development forecast 2018-2023

Main market players of Sorafenib in EMEA, with company and product introduction, position in the Sorafenib market

Market status and development trend of Sorafenib by types and applications Cost and profit status of Sorafenib, and marketing status Market growth drivers and challenges

The report segments the EMEA Sorafenib market as:

EMEA Sorafenib Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe Middle East Africa

EMEA Sorafenib Market: Product Type Segment Analysis (Consumption Volume,



Average Price, Revenue, Market Share and Trend 2013-2023):

Capsule

Tablet

EMEA Sorafenib Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital Pharmacy Retail Pharmacy Online Pharmac

EMEA Sorafenib Market: Players Segment Analysis (Company and Product introduction, Sorafenib Sales Volume, Revenue, Price and Gross Margin):

Pfizer

Allergan

Alnylam Pharmaceuticals

Acceleron Pharma

Biocon

Bionomics

CASI Pharmaceuticals

Celgene Corporation

Enzon Pharmaceuticals

Five Prime Therapeutics

Fujifilm Kyowa Kirin Biologics

Genentech

Genexine

Hetero Drugs

ImClone Systems

Intas Pharmaceuticals

Levolta Pharmaceuticals

Mabtech

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF SORAFENIB

- 1.1 Definition of Sorafenib in This Report
- 1.2 Commercial Types of Sorafenib
 - 1.2.1 Capsule
 - 1.2.2 Tablet
- 1.3 Downstream Application of Sorafenib
 - 1.3.1 Hospital Pharmacy
- 1.3.2 Retail Pharmacy
- 1.3.3 Online Pharmac
- 1.4 Development History of Sorafenib
- 1.5 Market Status and Trend of Sorafenib 2013-2023
- 1.5.1 EMEA Sorafenib Market Status and Trend 2013-2023
- 1.5.2 Regional Sorafenib Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Sorafenib in EMEA 2013-2017
- 2.2 Consumption Market of Sorafenib in EMEA by Regions
 - 2.2.1 Consumption Volume of Sorafenib in EMEA by Regions
 - 2.2.2 Revenue of Sorafenib in EMEA by Regions
- 2.3 Market Analysis of Sorafenib in EMEA by Regions
 - 2.3.1 Market Analysis of Sorafenib in Europe 2013-2017
 - 2.3.2 Market Analysis of Sorafenib in Middle East 2013-2017
 - 2.3.3 Market Analysis of Sorafenib in Africa 2013-2017
- 2.4 Market Development Forecast of Sorafenib in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Sorafenib in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Sorafenib by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
- 3.1.1 Consumption Volume of Sorafenib in EMEA by Types
- 3.1.2 Revenue of Sorafenib in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe
 - 3.2.2 Market Status by Types in Middle East



- 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Sorafenib in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Sorafenib in EMEA by Downstream Industry
- 4.2 Demand Volume of Sorafenib by Downstream Industry in Major Countries
- 4.2.1 Demand Volume of Sorafenib by Downstream Industry in Europe
- 4.2.2 Demand Volume of Sorafenib by Downstream Industry in Middle East
- 4.2.3 Demand Volume of Sorafenib by Downstream Industry in Africa
- 4.3 Market Forecast of Sorafenib in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF SORAFENIB

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Sorafenib Downstream Industry Situation and Trend Overview

CHAPTER 6 SORAFENIB MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Sorafenib in EMEA by Major Players
- 6.2 Revenue of Sorafenib in EMEA by Major Players
- 6.3 Basic Information of Sorafenib by Major Players
 - 6.3.1 Headquarters Location and Established Time of Sorafenib Major Players
 - 6.3.2 Employees and Revenue Level of Sorafenib Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 SORAFENIB MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Pfizer
 - 7.1.1 Company profile
 - 7.1.2 Representative Sorafenib Product
 - 7.1.3 Sorafenib Sales, Revenue, Price and Gross Margin of Pfizer
- 7.2 Allergan



- 7.2.1 Company profile
- 7.2.2 Representative Sorafenib Product
- 7.2.3 Sorafenib Sales, Revenue, Price and Gross Margin of Allergan
- 7.3 Alnylam Pharmaceuticals
 - 7.3.1 Company profile
 - 7.3.2 Representative Sorafenib Product
 - 7.3.3 Sorafenib Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals
- 7.4 Acceleron Pharma
 - 7.4.1 Company profile
 - 7.4.2 Representative Sorafenib Product
 - 7.4.3 Sorafenib Sales, Revenue, Price and Gross Margin of Acceleron Pharma
- 7.5 Biocon
 - 7.5.1 Company profile
 - 7.5.2 Representative Sorafenib Product
 - 7.5.3 Sorafenib Sales, Revenue, Price and Gross Margin of Biocon
- 7.6 Bionomics
 - 7.6.1 Company profile
 - 7.6.2 Representative Sorafenib Product
 - 7.6.3 Sorafenib Sales, Revenue, Price and Gross Margin of Bionomics
- 7.7 CASI Pharmaceuticals
 - 7.7.1 Company profile
 - 7.7.2 Representative Sorafenib Product
 - 7.7.3 Sorafenib Sales, Revenue, Price and Gross Margin of CASI Pharmaceuticals
- 7.8 Celgene Corporation
 - 7.8.1 Company profile
 - 7.8.2 Representative Sorafenib Product
 - 7.8.3 Sorafenib Sales, Revenue, Price and Gross Margin of Celgene Corporation
- 7.9 Enzon Pharmaceuticals
 - 7.9.1 Company profile
 - 7.9.2 Representative Sorafenib Product
- 7.9.3 Sorafenib Sales, Revenue, Price and Gross Margin of Enzon Pharmaceuticals
- 7.10 Five Prime Therapeutics
 - 7.10.1 Company profile
 - 7.10.2 Representative Sorafenib Product
 - 7.10.3 Sorafenib Sales, Revenue, Price and Gross Margin of Five Prime Therapeutics
- 7.11 Fujifilm Kyowa Kirin Biologics
 - 7.11.1 Company profile
 - 7.11.2 Representative Sorafenib Product
- 7.11.3 Sorafenib Sales, Revenue, Price and Gross Margin of Fujifilm Kyowa Kirin



Biologics

- 7.12 Genentech
 - 7.12.1 Company profile
 - 7.12.2 Representative Sorafenib Product
 - 7.12.3 Sorafenib Sales, Revenue, Price and Gross Margin of Genentech
- 7.13 Genexine
 - 7.13.1 Company profile
 - 7.13.2 Representative Sorafenib Product
 - 7.13.3 Sorafenib Sales, Revenue, Price and Gross Margin of Genexine
- 7.14 Hetero Drugs
 - 7.14.1 Company profile
 - 7.14.2 Representative Sorafenib Product
 - 7.14.3 Sorafenib Sales, Revenue, Price and Gross Margin of Hetero Drugs
- 7.15 ImClone Systems
 - 7.15.1 Company profile
 - 7.15.2 Representative Sorafenib Product
 - 7.15.3 Sorafenib Sales, Revenue, Price and Gross Margin of ImClone Systems
- 7.16 Intas Pharmaceuticals
- 7.17 Levolta Pharmaceuticals
- 7.18 Mabtech

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF SORAFENIB

- 8.1 Industry Chain of Sorafenib
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF SORAFENIB

- 9.1 Cost Structure Analysis of Sorafenib
- 9.2 Raw Materials Cost Analysis of Sorafenib
- 9.3 Labor Cost Analysis of Sorafenib
- 9.4 Manufacturing Expenses Analysis of Sorafenib

CHAPTER 10 MARKETING STATUS ANALYSIS OF SORAFENIB

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing



- 10.1.2 Indirect Marketing
- 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Sorafenib-EMEA Market Status and Trend Report 2013-2023

Product link: https://marketpublishers.com/r/S0250570DBDEN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/S0250570DBDEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970